Braidwell’s Milestone Pharmaceuticals MIST Stock Holding History

Braidwell’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,164,849	Closed	-$4.61M	–	89
2022 Q4	$4.61M	Buy	+1,164,849	New	+$6.13M	0.15%	84

Other funds holding MIST

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's MIST Position: Q1 2023 in Review

Braidwell sold out of Milestone Pharmaceuticals (MIST) in Q1 2023, closing a stake of 1,164,849 shares — an estimated $4.61M sold.

Braidwell first reported a position in MIST in Q4 2022 and held it in 1 quarter. The position peaked at $4.61M in Q4 2022. 50 funds tracked by Wall St. Rank hold MIST as of Q1 2023.

Braidwell reported no remaining Milestone Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Braidwell sold 1,164,849 Milestone Pharmaceuticals shares in Q1 2023, an estimated $4.61M.
Braidwell first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Braidwell's Milestone Pharmaceuticals position peaked at $4.61M in Q4 2022.
50 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2023.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.